Onconova Therapeutics, Inc. to Present Corporate Overview at Biotech Showcase 2017
January 05 2017 - 8:30AM
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage
biopharmaceutical company focused on discovering and developing
novel products to treat cancer, today announced that Ramesh Kumar,
Ph.D., President and Chief Executive Officer, will present a
company overview at the Biotech Showcase 2017 being held at the
Hilton Hotel in San Francisco, CA.
The presentation details are:
Date: Wednesday, January 11, 2017 Time: 2:00 PM Track: Room 7
(Ballroom Level)
To view the corporate presentation, please click here.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a Phase 3 clinical-stage
biopharmaceutical company focused on discovering and developing
novel products to treat cancer, with primary focus on
Myelopdysplastic Syndromes. Onconova's clinical and pre-clinical
stage drug development candidates are derived from its extensive
chemical library and are designed to work against specific cellular
pathways that are important in cancer cells, while causing minimal
damage to normal cells. The Company's most advanced product
candidate, rigosertib, is a small molecule inhibitor of cellular
signaling and acts as a RAS mimetic. These effects of rigosertib
appear to be mediated by direct binding of the compound to the
RAS-binding domain (RBD) found in many RAS effector proteins,
including the Raf kinases and PI3 Kinase. Rigosertib is protected
by issued patents (earliest expiry in 2026) and has been awarded
Orphan Designation for MDS in the United States, Europe and Japan.
In addition to rigosertib, two other candidates are clinical stage,
and several candidates are in pre-clinical stages. For more
information, please visit http://www.onconova.com.
Forward Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, Section 21E of the Securities Exchange Act of
1934, as amended, and the Private Securities Litigation Reform Act
of 1995, which involve risks and uncertainties. These statements
relate to future events or Onconova Therapeutics, Inc.'s future
operations, clinical development of Onconova's product candidates
and presentation of data with respect thereto, regulatory
approvals, expectations regarding the sufficiency of Onconova's
cash and other resources to fund operating expenses and capital
expenditures, Onconova's anticipated milestones and future
expectations and plans and prospects. Although Onconova believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, expectations may prove to have
been materially different from the results expressed or implied by
such forward-looking statements. Onconova has attempted to identify
forward-looking statements by terminology including "believes,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "should," "approximately" or other words that
convey uncertainty of future events or outcomes. These statements
are only predictions and involve known and unknown risks,
uncertainties, and other factors, including Onconova's need for
additional financing and current plans and future needs to scale
back operations if adequate financing is not obtained, the success
and timing of Onconova's clinical trials and regulatory approval of
protocols, and those discussed under the heading "Risk Factors" in
Onconova's most recent Annual Report on Form 10-K and quarterly
reports on Form 10-Q. Any forward-looking statements contained in
this release speak only as of its date. Onconova undertakes no
obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
GENERAL CONTACT:
http://www.onconova.com/contact/
INVESTOR RELATIONS CONTACT:
Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics
Lisa.sher@mbsvalue.com
(212) 750-5800
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024